Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

n November 2007.

"Since we announced our Action Agenda in 2003, we have been steadily building a strong, high-performance company for the long term," said Hassan. "We are seeing that the acquisition of OBS was a smart, pivotal move in our transformation journey."

Integration of OBS continues to progress well, as evidenced by the following highlights:

-- In the human prescription and animal health areas, the executive teams

and organizational structures are in place and operating at all levels;

-- Cost synergies are being realized;

-- In R&D, an extensive review of the pipeline portfolio is ongoing.

First Quarter 2008 Results

For the 2008 first quarter, Schering-Plough reported net income available to common shareholders of $253 million or 15 cents per common share on a GAAP basis. Earnings per common share for the 2008 first quarter would have been 53 cents on net income of $862 million on a reconciled basis, which excludes purchase accounting adjustments and acquisition-related items for the OBS acquisition and other specified items. For the 2007 first quarter, Schering-Plough reported net income available to common shareholders of $543 million or 36 cents per common share on a GAAP basis and 42 cents per common share on a reconciled basis.

GAAP net sales for the 2008 first quarter totaled $4.7 billion, including $1.3 billion as a result of the OBS acquisition. The overall sales increase of

56 percent includes the impact of the OBS net sales and a favorable impact of 7 percent from foreign exchange on stand-alone Schering-Plough sales.

Global cholesterol joint venture net sales, which include VYTORIN and ZETIA, totaled $1.2 billion in the 2008 first quarter. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. Including an adjustment of an assumed 50 percent of the global cholesterol joint ventur
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... 2014 About POCT ... a clinical laboratory. It helps in making fast ... and medication. POCT is gaining popularity due to ... such as diabetes, heart disease, and obesity. It ... standardized to minimize errors during the diagnosis of ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... have found a defense against the Black Plague, a disease ... Middle Ages and which government agencies perceive as a terrorist ... team have developed a vaccine that early research shows is ... of Health and USDA funded research appear in the August ...
... COLLEGE STATION, Sept. 24, 2008 America,s war on ... agents, and Texas A&M University chemist Dr. Frank Raushel ... that might neutralize one such chemical agent, the organophosphates. ... the 1930s but soon made their way into the ...
... (Nasdaq: SVNT ) today announced that Christopher,Clement, President ... corporate update at the upcoming Lazard Capital Markets 5th,Annual ... on Tuesday, November 18, 2008 at,9:25 a.m. ET. The ... in New,York City November 18-19, 2008., Individuals can ...
Cached Biology Technology:UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3Researcher working on destruction of chemical weapons 2Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2
(Date:9/21/2014)... are set to rise again in 2014 - reaching a ... cent projected rise in burning fossil fuels is revealed by ... by researchers at the Tyndall Centre for Climate Change Research ... Engineering, Mathematics and Physical Sciences at the University of Exeter. ... where world leaders will seek to catalyse action on climate ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
(Date:9/21/2014)... mussels and barnacles secrete very sticky proteins that help ... Inspired by these natural adhesives, a team of MIT ... to repair ships or help heal wounds and surgical ... MIT researchers engineered bacteria to produce a hybrid material ... a bacterial protein found in biofilms slimy layers ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... (Boston) Boston University School of Medicine (BUSM) ... physiology, with joint appointments in biomedical engineering and medicine, ... Lipids. This award is being bestowed by ... in the application of nuclear magnetic resonance methods to ...
... This release is available in Spanish . ... (ARS) scientists are helping to increase understanding about the ... with potent antioxidant properties, in oat grain. Avns ... their many health benefits. The specific purpose of Avns ...
... , AUGUSTA, Ga. In a first-of-its-kind study, ... simulation driving can reduce Parkinson,s patients, threefold increased ... disease are three times more likely to have ... cognitive, motor and visuospatial impairments. Previous ...
Cached Biology News:Studies provide insight into key oat chemical 2Simulation study may help Parkinson's patients retain driving skills 2
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
... Silver Staining Kit is uniquely formulated ... with minimal protein modification for optimal ... problems associated with traditional silver stains ... because the reagents used do not ...
...
Biology Products: